|
Steven A. Kriegsman is president chief executive officer and a director of CytRx Corporation a clinical-stage biopharmaceutical company engaged in developing human therapeutic products. He also serves as a director of RXi. He previously served as a director and chairman of Global Genomics from June 2000 until its merger with Global Genomics in July 2002. Mr. Kriegsman is the chairman of the board and founder of Kriegsman Capital Group LLC a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. He has advised such companies as SuperGen Inc. Closure Medical Corporation Novoste Corporation Miravant Medical Technologies and Maxim Pharmaceuticals. Mr. Kriegsman has a B.S. degree with honors from New York University in accounting and completed the Executive Program in Mergers and Acquisitions at New York University The Management Institute. Mr. Kriegsman was formerly a Certified Public Accountant with KPMG in New York City. From June 2003 until February 2008 he served as a director and he is the former chairman of the audit committee of Bradley Pharmaceuticals Inc. In February 2006 Mr. Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006 he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Mr. Kriegsman has been active in various charitable organizations including the Biotechnology Industry Organization the ALS Association the Los Angeles Venture Association the Southern California Biomedical Council and the Palisades-Malibu YMCA. | 